New drug duo targets Hard-to-Treat colorectal cancer
NCT ID NCT07691489
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This trial investigates whether combining two drugs—trastuzumab deruxtecan (T-DXd) and cetuximab—can shrink tumors in people with advanced colorectal cancer that has low levels of the HER2 protein and has worsened after standard treatments. The study enrolls adults with metastatic or unresectable colon or rectal cancer. The main goal is to see how many participants respond to the combination therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trastuzumab deruxtecan (T-DXd) and cetuximab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with HER2-low colorectal cancer who have run out of standard therapies.
- What could go wrong
- This is a small, early-phase trial (Phase 2) with only 27 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE COLON are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, 10604, United States
-
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering at Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering at Nassau (Limited Protocol Activities)
Uniondale, New York, 11553, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?